Haruaki Nobori

Toyonaka, 5610825, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Discovery of the Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19.

Discovery of the Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19.

Journal: Journal of medicinal chemistry
Published: July 05, 2025

Ensitrelvir suppresses prolonged olfactory abnormalities derived from SARS-CoV-2 infection in hamsters.

Ensitrelvir suppresses prolonged olfactory abnormalities derived from SARS-CoV-2 infection in hamsters.

Journal: Antiviral research
Published: January 13, 2025

Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CLpro detected in the SCORPIO-SR phase 3 trial.

Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CLpro detected in the SCORPIO-SR phase 3 trial.

Journal: Antiviral research
Published: November 11, 2024

Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission model.

Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission model.

Journal: Antiviral research
Published: August 21, 2024

Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.

Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.

Journal: Antiviral research
Published: November 29, 2023

2-thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses.

2-thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: October 13, 2023

Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.

Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.

Journal: Viruses
Published: July 23, 2023

Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in a COVID-19 hamster model.

Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in a COVID-19 hamster model.

Journal: EBioMedicine
Published: June 21, 2023

Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.

Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.

Journal: Biochemical and biophysical research communications
Published: December 27, 2022

S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.

S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.

Journal: Science translational medicine
Published: November 03, 2022

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.

Journal: The Journal of antimicrobial chemotherapy
Published: October 17, 2022

Identification of cap-dependent endonuclease inhibitors with broad-spectrum activity against bunyaviruses.

Identification of cap-dependent endonuclease inhibitors with broad-spectrum activity against bunyaviruses.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 29, 2022
Showing 1-12 of 23

Last Updated: 09/26/2026